ZHANG Xiran,ZHANG Xinxin,KANG Zhiming,et al.Advances in ocular surface and intestinal flora of patients with thyroid-associated ophthalmopathy[J].Recent Advances in Ophthalmology,2024,44(6):494-498.[doi:10.13389/j.cnki.rao.2024.0095]





Advances in ocular surface and intestinal flora of patients with thyroid-associated ophthalmopathy
030001 山西省太原市,山西医科大学第一临床医学院(张皙苒);030002 山西省太原市,山西省眼科医院微生物重点实验室(张馨心,康志明,董魁);030002 山西省太原市,山西省眼科医院眼眶病科(孙斌)
ZHANG Xiran1ZHANG Xinxin2KANG Zhiming2DONG Kui2SUN Bin3
1.First Clinical College of Shanxi Medical University,Taiyuan 030001,Shanxi Province,China
2.Central Microbiology Laboratory,Shanxi Eye Hospital,Taiyuan 030002,Shanxi Province,China
3.Department of Orbital Ophthalmology,Shanxi Eye Hospital,Taiyuan 030002,Shanxi Province,China
thyroid-associated ophthalmopathy intestinal flora ocular surface flora gut-eye axis
Thyroid-associated ophthalmopathy (TAO) is an autoimmune disease whose etiology and pathogenesis have not yet been clarified. It is generally believed that its occurrence is the result of a combination of immune, genetic, environmental, and other factors. In recent years, scholars have paid more attention to the influence of microorganisms on TAO, and they found that alterations of the ocular surface and intestinal flora can stimulate the immune system to generate a series of immune responses, which induces autoimmune responses to TAO. The “gut-eye axis” may be an important factor involved in the development of TAO. The intestinal flora and its metabolites may affect ocular tissues through blood circulation and the lymphatic system. This interaction between the gut and eye axis may affect the occurrence and development of TAO through various pathways, including migration of immune cells, cross immune reactions, and metabolite circulation. This article reviews the research progress on the correlation between alterations of the ocular surface and intestinal flora and TAO and explores the possible mechanisms of the flora involvement in the development of TAO, providing new ideas for the diagnosis and treatment of TAO.


[1] PETRILLO F,PJGNATARO D,LAVANO M A,SANTELLA B,FOLLIERO V,ZANNELLA C,et al.Current evidence on the ocular surface microbiota and related diseases[J].Microorganisms,2020,8(7):1033-1046.
[2] RAMPANELLI E,NIEUWDORP M.Gut microbiome in type 1 diabetes:the immunological perspective[J].Expert Rev Clin Immunol,2023,19(1):93-109.
[3] JI X,DONG K,PU J,YANG J,ZHANG Z,NING X,et al.Comparison of the ocular surface microbiota between thyroid-associated ophthalmopathy patients and healthy subjects[J].Front Cell Infect Microbiol,2022,12:914749.
[4] BISCARINI F,MASETTI G,MULLER I,VERHASSELT H L,COVELLI D,COLUCCI G,et al.Gut microbiome associated with graves’ disease and graves’ orbitopathy:the INDIGO multi-centre european study[J].J Clin Endocrinol Metab,2023,108(8):2065-2077.
[5] DAVIES T F,ANDERSEN S,LATIF R,NAGAYAMA Y,BARBESINO G,BRITO M,et al.Graves’ disease[J].Nat Rev Dis Primers,2020,6(1):52-75.
[6] SMITH T J,JANSSEN J.Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy[J].Endocr Rev,2019,40(1):236-67.
[7] GIRNITA L,SMITH T J,JANSSEN J.It takes two to tango:IGF-I and TSH receptors in thyroid eye disease[J].J Clin Endocrinol Metab,2022,107(Suppl 1):S1-S12.
[8] ROOS J C P,PAULPANDIAN V,MUREHY R.Serial TSH-receptor antibody levels to guide the management of thyroid eye disease:the impact of smoking,immunosuppression,radio-iodine,and thyroidectomy[J].Eye (Lond),2019,33(2):212-217.
[9] TAY W L,TONG A K T,HUI K Y D,TANG Y L C,CHNG C L.Radioiodine associated de novo graves’ opthalmopathy in an Asian cohort[J].Hell J Nucl Med,2017,20(3):227-231.
[10] ROTONDO DOTTORE G,LEO M,CASINI G,LATROFA F,CESTARI L,SELLARI-FRANCESCHINI S,et al.Antioxidant actions of selenium in orbital fibroblasts:a basis for the effects of selenium in graves’ orbitopathy[J].Thyroid,2017,27(2):271-278.
[11] JANYGA S,MAREK B,KAJDANIUK D,OGRODOWCYK-BOBIK M,URBANEK A,BUDAK .CD4+ cells in autoimmune thyroid disease[J].Endokrynol Pol,2021,72(5):572-583.
[12] MASETTI G,LUDGATE M.Microbiome and graves’ orbitopathy[J].Eur Thyroid J,2020,9(Suppl 1):78-85.
[13] ZHANG Z,ZOU X,XUE W,ZHANG P,WANG S,ZOU H.Ocular surface microbiota in diabetic patients with dry eye disease[J].Invest Ophthalmol Vis Sci,2021,62(12):13-22.
[14] ARAGONA P,BAUDOUIN C,BENITEZ DEl CASTILLO J M,MESSMER E,BARABINO S,MERAYO-LLOVES J,et al.The ocular microbiome and microbiota and their effects on ocular surface pathophysiology and disorders[J].Surv Ophthalmol,2021,66(6):907-925.
[15] CHENG P,DONG K,KANG Z,LI J,WANG W,ZHANG X,et al.Application of high-throughput sequencing technology in identifying the pathogens in endophthalmitis[J].J Ophthalmol,2022,2022:4024260.
[16] GARZA A,DIAZ G,HAMDAN M,SHETTY A,HONG B Y,CERVANTES J.Homeostasis and defense at the surface of the eye.The conjunctival microbiota[J].Curr Eye Res,2021,46(1):1-6.
[17] ST LEGER A J,DESAI J V,DRUMMOND R A,KUGADAS A,AlMAGHRABI F,SILVER P,et al.An ocular commensal protects against corneal infection by driving an interleukin-17 response from mucosal γδ T Cells[J].Immunity,2017,47(1):148-158.e5.
[18] NAPOLITANO P,FILIPPELLI M,DAVINELLI S,BARTOLLINO S,DELL’OMO R,COSTAGLIOLA C.Influence of gut microbiota on eye diseases:an overview[J].Ann Med,2021,53(1):750-761.
[19] CAVUOTO K M,BANERJEE S,GALOR A.Relationship between the microbiome and ocular.health[J].Ocul Surf,2019,17(3):384-392.
[20] SHI T T,XIN Z,HUA L,ZHAO R X,YANG Y L,WANG H,et al.Alterations in the intestinal.microbiota of patients with severe and active Graves’ orbitopathy:a cross-sectional study[J].J Endocrinol Invest,2019,42(8):967-978.
[21] SHI T T,HUA L,WANG H,XIN Z.The potential link between gut microbiota and serum TRAb in chinese patients with severe and active graves’ orbitopathy[J].Int J Endocrinol,2019,2019:9736968.
[22] MOSHKELGOSHA S,VERHASSELT H L,MASETTI G,COVELLI D,BISCARINI F,HORSTMANN M,et al.Modulating gut microbiota in a mouse model of graves’ orbitopathy and its impact on induced disease[J].Microbiome,2021,9(1):45-65.
[23] MASETTI G,MOSHKELGOSHA S,KHLING H L,COVELLI D,BANGA J P,BERCHNER-PFANNSCHMIDT U,et al.Gut microbiota in experimental murine model of graves’ orbitopathy established in different environments may modulate clinical presentation of disease[J].Microbiome,2018,6(1):97-112.
[24] PRASAD R,ASARE-BEDIKO B,HARBOUR A,FLOYD J L,CHAKRABORTY D,DUAN Y,et al.Microbial signatures in the rodent eyes with retinal dysfunction and diabetic retinopathy[J].Invest Ophthalmol Vis Sci,2022,63(1):5-17.
[25] SCHAEFER L,HERNANDEZ H,COATS R A,YU Z,PFLUGFELDER S C,BRITTON R A,et al.Author correction:gut-derived butyrate suppresses ocular surface inflammation[J].Sci Rep,2022,12(1):6581.
[26] YANAGISAWA N,UESHIBA H,ABE Y,KATO H,HIGUCHI T,YAGI J.Outer membrane protein of gut commensal microorganism induces autoantibody production and extra-intestinal gland inflammation in mice[J].Int J Mol Sci,2018,19(10):3241.
[27] JIANG W,YU X,KOSIK R O,SONG Y,QIAO T,TONG J,et al.Gut microbiota may play a significant role in the pathogenesis of graves’ disease[J].Thyroid,2021,31(5):810-820.
[28] GONZALEZ-DIAZ S N,SANCHEZ-BORGES M,RANGEL-GONZALEZ D M,GUZMAN-AVILAN R I,CANSECO-VILLARREAL J I,ARIAS-CRUZ A.Chronic urticaria and thyroid pathology[J].World Allergy Organ J,2020,13(3):100101.
[29] HONDA K,LITTMAN D R.The microbiota in adaptive immune homeostasis and disease[J].Nature,2016,535(7610):75-84.
[30] WANG Y,MA X M,WANG X,SUN X,WANG L J,LI X Q,et al.Emerging insights into the role of epigenetics and gut microbiome in the pathogenesis of graves’ ophthalmopathy[J].Front Endocrinol (Lausanne),2021,12:788535.
[31] DEVI M B,SARMA H K,MUKHERJEE A K,KHAN M R.Mechanistic insights into immune-microbiota interactions and preventive role of probiotics against autoimmune diabetes mellitus[J].Probiotics Antimicrob Proteins,2023,15(4):983-1000.
[32] MACPHERSON A J,GEUKING M B,MCCOY K D.Immune responses that adapt the intestinal mucosa to commensal intestinal bacteria[J].Immunology,2005,115(2):153-162.
[33] JIANG W,LU G,GAO D,L Z,LI D.The relationships between the gut microbiota and its metabolites with thyroid diseases[J].Front Endocrinol (Lausanne),2022,13:943408.
[34] MORRISON D J,PRESTON T.Formation of short chain fatty acids by the gut microbiota and their.impact on human metabolism[J].Gut Microbes,2016,7(3):189-200.
[35] BAI X,XU Q,ZHANG W,WANG C.The gut-eye axis:correlation between the gut microbiota and.autoimmune dry eye in individuals with sjgren syndrome[J].Eye Contact Lens,2023,49(1):1-7.
[36] HAN Z,CEN C,OU Q,PAN Y,ZHANG J,HUO D,et al.The potential prebiotic berberine combined with methimazole improved the therapeutic effect of graves’ disease patients through regulating the intestinal microbiome[J].Front Immunol,2021,12:826067.
[37] TOUCH S,GODEFROY E,ROLHION N,DANNE C,OEUVRAY C,STRAUBE M,et al.Human CD4+CD8α+ Tregs induced by faecalibacterium prausnitzii protect against intestinal inflammation[J].JCI Insight,2022,7(12):e154722.
[38] El MENOFY N G,RAMADAN M,ABDELBARY E R,IBRAHIM H G,AZZAM A I,GHIT M M,et al.Bacterial compositional shifts of gut microbiomes in patients with rheumatoid arthritis in association with disease activity[J].Microorga-nisms,2022,10(9):1820.


[1]杨忠昆 朱勤 胡竹林.改良三壁眶减压术治疗重症甲状腺相关性眼病的疗效观察[J].眼科新进展,2012,32(9):000.
[2]陆燕,黄媛媛,蔡季平,等. SB431542和TGF-β1对甲状腺相关性眼病患者眼眶成纤维细胞α-SMA及CTGF基因表达的影响[J].眼科新进展,2015,35(3):210.[doi:10.13389/j.cnki.rao.2015.0057]
 LU Yan,HUANG Yuan-Yuan,CAl Ji-Ping,et al. Effects of SB431542 and TGF-B1 0n a-SMA and CTGF gene expression in orbital fibroblast of patients with thyroid-associated ophthalmolopathy[J].Recent Advances in Ophthalmology,2015,35(6):210.[doi:10.13389/j.cnki.rao.2015.0057]
 HE Zhiwei,HU Xin,CHEN Guofang,et al.Antioxidant: a new therapy for thyroid associated ophthalmopathy[J].Recent Advances in Ophthalmology,2022,42(6):417.[doi:10.13389/j.cnki.rao.2022.0085]
 ZHANG Hao,ZHAO Jing,GE Xiaoning,et al.Research progress in diagnostic biomarkers for thyroid-associated ophthalmopathy[J].Recent Advances in Ophthalmology,2022,42(6):562.[doi:10.13389/j.cnki.rao.2022.0115]


更新日期/Last Update: 2024-06-05